EP Patent

EP2988735A1 — Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof

Assigned to Pharmathen SA · Expires 2016-03-02 · 10y expired

What this patent protects

The present invention relates to a stable pharmaceutical formulation for oral administration comprising a therapeutically effective amount of a serotonin-norepinephrine reuptake inhibitor or a pharmaceutically acceptable salt thereof, in particular Duloxetine that inhibits degrad…

USPTO Abstract

The present invention relates to a stable pharmaceutical formulation for oral administration comprising a therapeutically effective amount of a serotonin-norepinephrine reuptake inhibitor or a pharmaceutically acceptable salt thereof, in particular Duloxetine that inhibits degradation and/or hydrolysis of the active ingredient. It also relates to a process for the preparation thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP2988735A1
Jurisdiction
EP
Classification
Expires
2016-03-02
Drug substance claim
No
Drug product claim
No
Assignee
Pharmathen SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.